Earnings Alerts

New China Life Insurance (601336) Earnings: YTD Premium Income Hits 155.63B Yuan with Optimized Business Structure

By November 15, 2024 No Comments
  • Year-to-date (YTD) premium income for New China Life has reached 155.63 billion yuan.
  • The company is focusing on optimizing its product structure, business structure, and overall quality.
  • Current investment recommendations for New China Life include 11 buys, 5 holds, and 4 sells.

A look at New China Life Insurance Smart Scores

FactorScoreMagnitude
Value4
Dividend4
Growth4
Resilience2
Momentum5
OVERALL SMART SCORE3.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, New China Life Insurance is positioned favorably for long-term growth and stability in the insurance sector. With strong scores across Value, Dividend, and Growth factors, the company demonstrates solid fundamentals and potential for future profitability. The high Momentum score further indicates positive market sentiment and a potential uptrend in the company’s performance.

Despite a lower Resilience score, New China Life Insurance‘s overall outlook remains robust, supported by its diverse portfolio of life, accident, and health insurance products. With a focus on both local and foreign markets, the company is well-positioned to capitalize on evolving consumer needs and economic trends in the insurance industry.

**Summary**: New China Life Insurance Company Limited provides a range of insurance products and services, including life, accident, and health insurance. With favorable Smartkarma Smart Scores in Value, Dividend, Growth, and Momentum, the company shows promise for long-term growth and stability in the insurance market.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars